Zentalis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZNTL research report →
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations.
- CEO
- Julia Marie Eastland
- IPO
- 2020
- Employees
- 106
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $317.49M
- P/E
- -2.58
- P/S
- 0.00
- P/B
- 1.72
- EV/EBITDA
- -2.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.61%
- ROIC
- -65.38%
- Revenue
- $0 · -100.00%
- Net Income
- $-137,060,000 · 17.35%
- EPS
- $-1.91 · 18.03%
- Op Income
- $-152,808,000
- FCF YoY
- 26.79%
- 52W High
- $6.95
- 52W Low
- $1.15
- 50D MA
- $3.96
- 200D MA
- $2.62
- Beta
- 1.93
- Avg Volume
- 2.25M
Get TickerSpark's AI analysis on ZNTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Johnson David Michael | other | 57,100 |
| Jun 16, 26 | Skvarka Jan | other | 57,100 |
| Jun 16, 26 | Walker Luke Nathaniel | other | 57,100 |
| Jun 16, 26 | Kariuki Enoch | other | 57,100 |
| Jun 16, 26 | Myers Scott Dunseth | other | 57,100 |
| May 26, 26 | Campbell Shannon | other | 114,200 |
| May 22, 26 | Campbell Shannon | other | 0 |
| Feb 6, 26 | Bruns Ingmar | sell | 2,962 |
| Feb 9, 26 | Bruns Ingmar | sell | 335 |
| Feb 6, 26 | Vultaggio Vincent | sell | 29,951 |
Our ZNTL coverage
Recent articles, reports, and earnings notes.
No research on ZNTL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZNTL report →Similar companies
Peers in the same neighborhood.